No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Neuren Pharmaceuticals Appoints Chief Regulatory Officer; Shares Up 8%
Australian Shares Rise Amidst Temporary Reprieve for Electronic Tariffs; EBR Systems Receives US FDA Approval for Heart Failure Treatment Device
Why DroneShield, Fiducian, Neuren, and Newmont Shares Are Storming Higher
Neuren Pharmaceuticals Confirms Primary Endpoints for Phase Three Phelan-McDermid Syndrome Drug Candidate Trial
Guess Which ASX 200 Stock Is Surging 18% on Big News
Neuren Pharmaceuticals Ltd: 2024 Annual Report to shareholders